BCL2 and B-cell chronic lymphocytic leukemia: An early Phase II clinical trial revealed that in newly diagnosed CLL patients, the ORR of Rituximab combined with the BCL-2 inhibitor Navitoclax was 70%, whereas the ORR of Rituximab alone was 35% (NCT01087151) [54].